CYDY CytoDyn Inc.

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$1.53    OTCQB
As of 09/15/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  11/17/2005
Outstanding shares:  644,196,206
Average volume:  1,812,375
Market cap:   $982,399,214
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -24.02
PB ratio:   -91.11
PS ratio:   -781.54
Return on equity:   735.91%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy